Preconditioning of Human Mesenchymal Stem Cells to Enhance Their Regulation of the Immune Response

Stem Cells International - Tập 2016 Số 1 - 2016
Arman Saparov1, Vyacheslav Ogay2, Talgat Nurgozhin3, Medet Jumabay4, Chien‐Wen Chen5
1Department of Biomedical Sciences, Nazarbayev University School of Medicine, Astana 010000, Kazakhstan
2Stem Cell Laboratory, National Center for Biotechnology, Astana 010000, Kazakhstan
3Center for Life Sciences, Nazarbayev University, Astana 010000, Kazakhstan
4Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
5Research Laboratory of Electronics and Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

Tóm tắt

Mesenchymal stem cells (MSCs) have attracted the attention of researchers and clinicians for their ability to differentiate into a number of cell types, participate in tissue regeneration, and repair the damaged tissues by producing various growth factors and cytokines, as well as their unique immunoprivilege in alloreactive hosts. The immunomodulatory functions of exogenous MSCs have been widely investigated in immune‐mediated inflammatory diseases and transplantation research. However, a harsh environment at the site of tissue injury/inflammation with insufficient oxygen supply, abundance of reactive oxygen species, and presence of other harmful molecules that damage the adoptively transferred cells collectively lead to low survival and engraftment of the transferred cells. Preconditioning of MSCs ex vivo by hypoxia, inflammatory stimulus, or other factors/conditions prior to their use in therapy is an adaptive strategy that prepares MSCs to survive in the harsh environment and to enhance their regulatory function of the local immune responses. This review focuses on a number of approaches in preconditioning human MSCs with the goal of augmenting their capacity to regulate both innate and adaptive immune responses.

Từ khóa


Tài liệu tham khảo

10.1016/j.stem.2011.06.008

10.3390/ijms140816258

10.1038/ni.3002

10.1038/cdd.2015.168

10.1155/2016/3753581

10.1155/2016/1314709

10.1155/2016/1859567

10.1016/j.stem.2013.09.006

10.1016/j.jcyt.2015.10.011

10.1111/nyas.12815

10.1016/j.stem.2015.06.007

10.1038/cddis.2015.327

10.1371/journal.pone.0138477

10.1016/j.pharmthera.2013.12.002

10.1634/stemcells.2007-1104

10.1002/stem.1976

10.1007/s12035-014-8912-5

10.5966/sctm.2015-0211

10.1007/s00441-014-1830-z

10.1111/jcmm.12651

10.1002/stem.1400

10.1016/j.imlet.2015.06.005

10.1038/nri3209

10.1038/leu.2011.108

10.1371/journal.pone.0096161

10.1089/scd.2013.0028

10.1038/mt.2011.189

10.1038/cmi.2012.40

10.1007/s12015-012-9364-9

10.1089/scd.2009.0418

10.1186/s12967-015-0642-6

10.1038/ni.3146

10.1016/j.jcyt.2016.02.002

10.1002/btpr.2103

10.1038/srep08733

10.1002/1873-3468.12200

10.1002/stem.1191

10.1002/stem.1499

10.1073/pnas.1008117107

10.1016/j.jcyt.2013.09.004

10.1016/j.jcyt.2014.07.010

10.1016/j.imlet.2015.06.003

10.1016/j.autrev.2011.01.005

10.1182/blood-2004-04-1559

10.1038/bmt.2008.56

10.1002/stem.68

10.1136/annrheumdis-2011-200985

10.1111/j.1600-6143.2009.02721.x

10.1186/s13287-015-0178-y

10.1016/j.biochi.2013.07.011

10.1002/cbf.3125

10.1007/s13277-015-4664-8

10.1177/0022034514557671

10.3389/fimmu.2013.00203

10.3727/096368912x636984

10.1089/scd.2012.0386

10.1155/2016/4726267

10.1634/stemcells.2005-0008

10.1038/icb.2010.47

10.4049/jimmunol.1301828

10.1038/srep26345

10.1038/cdd.2013.158

10.1016/j.jcyt.2013.11.008

10.1016/j.jcyt.2015.07.018

10.1371/journal.pone.0009016

10.1002/stem.2075

10.1002/eji.201343335

10.1016/j.immuni.2014.06.011

10.1038/srep04645

10.1002/stem.1285

10.1161/circresaha.108.187724

Thông tin
Thông tin xuất bản

Stem Cells International

Tập 2016 Số 1

Thông tin tác giả